```json
{
"ranked_hypotheses": [
{
"rank": 1,
"title": "SV2A glycosylation as modulator of levetiracetam efficacy in AD",
"mechanism": "SV2A hypoglycosylation in AD alters levetiracetam binding affinity, explaining variable drug response across AD patients.",
"target_gene": "SV2A (SLC5A6)",
"confidence_score": 0.7,
"novelty_score": 0.6,
"feasibility_score": 0.7,
"impact_score": 0.8,
"composite_score": 0.71,
"testable_prediction": "Measure SV2A glycosylation status in AD patient samples from existing levetiracetam trials (NCT03489044) and correlate glycosylation level with drug responsiveness.",
"skeptic_concern": "Causal direction remains unclear—glycosylation defects could be downstream of hyperexcitability rather than upstream drivers."
},
{
"rank": 2,
"title": "Synaptic vesicle protein hypoglycosylation impairs release probability compensation",
"mechanism": "Altered glycosyltransferase expression in AD presynaptic terminals produces hypoglycosylated SV proteins that fail to support proper SNARE complex interactions during high-frequency firing.",
"target_gene": "SV2A",
"confidence_score": 0.6,
"novelty_score": 0.7,
"feasibility_score": 0.5,
"impact_score": 0.7,
"composite_score": 0.64,
"testable_prediction": "Use CRISPR/Cas9 to knockout MGAT1 glycosyltransferase in glutamatergic neurons derived from AD iPSCs and measure single-cell vesicular release kinetics under stimulus trains.",
"skeptic_concern": "CSF SV2A elevation observed in AD (PMID:29953872) more parsimoniously reflects compensatory vesicle trafficking rather than indicating a specific glycosylation defect."
},
{
"rank": 3,
"title": "SV2A glycosylation as a biomarker of synaptic resilience",
"mechanism": "The ratio of glycosylated to unglycosylated SV2A reflects synaptic capacity to resist excitotoxic damage, with higher glycosylation indicating preserved vesicle recruitment reserves.",
"target_gene": "SV2A (SLC5A6)",
"confidence_score": 0.5,
"novelty_score": 0.6,
"feasibility_score": 0.6,
"impact_score": 0.6,
"composite_score": 0.54,
"testable_prediction": "Develop a glycan-specific antibody to distinguish glycosylated SV2A from total SV2A and validate in longitudinal cohorts against cognitive decline rates.",
"skeptic_concern": "Currently no methods exist to assess SV2A glycosylation status in living patients; requires novel biomarker development before hypothesis testing."
}
],
"consensus_points": [
"SV2A protein modifications are implicated in AD synaptic dysfunction",
"Levetiracetam (existing antiepileptic targeting SV2A) is already in AD clinical trials",
"Synaptic dysfunction biomarkers (NfL, neurogranin) are clinically validated for AD progression"
],
"dissent_points": [
"Theorist asserts glycosylation defects precede and cause hyperexcitability; Skeptic argues CSF SV2A elevation indicates the opposite causal direction (hyperexcitability causes compensatory trafficking)"
],
"debate_summary": "The debate converged on SV2A glycosylation as the highest-priority target for investigation, with the Expert and Skeptic agreeing that its translational potential lies in modulating existing drug efficacy. The central unresolved dispute concerns causal direction—whether glycosylation defects drive hyperexcitability or are downstream consequences of it—which can only be resolved by prospective glycosylation measurements in longitudinal cohorts."
}
```